A National, Theranostic Cyclotron Resource to Drive Fundamental and Translational Medical Science

推动基础和转化医学科学的国家治疗诊断回旋加速器资源

• 批准号: 10795184
• 负责人: Robert Neal Golden
• 金额: $ 800万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-14 至 2028-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10795184
• 关键词: Alzheimer' s Disease; Alzheimer' s disease patient; Area; Award; Basic Science; Biomedical Research; Clinical; Clinical Research; Clinical Services; Cyclotrons; Department of Energy; Diagnostic Procedure; Discipline of Nuclear Medicine; Funding; Genetic; Growth; Health; Image; Investigation; Isotopes; Malignant Neoplasms; Medical; Medical Research; Nerve Degeneration; Parkinson Disease; Positron-Emission Tomography; Primates; Principal Investigator; Production; Public Health; Radiation therapy; Radioisotopes; Radiopharmaceuticals; Research; Resources; Science; Therapeutic procedure; United States; Universities; Viral; Wisconsin; animal imaging; base; chronic pain; clinical diagnostics; medical schools; meetings; novel diagnostics; novel therapeutics; particle therapy; pre-clinical research; research facility; research study; single photon emission computed tomography; stem cells; theranostics; therapy development

PROJECT SUMMARY/ABSTRACT The Cyclotron Group at the University of Wisconsin–Madison (UW) produces radionuclides for medical and fundamental scientific investigations using a 16 MeV General Electric PETtrace cyclotron. This effort currently supports $237M of funded research led by UW principal investigators (PIs), an additional $95M in projects led by a nationally distributed user base, an estimated clinical service revenue of almost $1M per year, and its own internal portfolio of federal awards of approximately $1.2M per year. The broad base of stakeholders includes PIs in 12 UW departments and over three dozen clinical research studies. Recent growth in nuclear medicine applications of cyclotron-produced radionuclides has been dramatic, and demand exceeded production capacity on multiple occasions in 2022, despite the Cyclotron Group’s prioritization of UW clinical and basic research needs. To create independent UW production capacity of increasingly promising single photon-emitting computed tomography (SPECT) and theranostic radionuclides, this proposal will build a new cyclotron facility to house a commercial 30 MeV cyclotron adjacent to the existing School of Medicine and Public Health (SMPH) biomedical research facilities of the Wisconsin Institutes for Medical Research (WIMR). This machine will add capacity in every essential area: standard and radiometal PET radionuclides, theranostic beta and Auger- emitters, and both clinical and research application-oriented research. The new machine will also enhance the efficacy of the existing PETtrace cyclotron, focusing each machine’s efforts on its strengths and simultaneously supporting a nascent UW Institute for Theranostics and Particle Therapy; the Waisman Center’s and Alzheimer’s Disease Research Center’s portfolio of neurodegenerative imaging trials; the preclinical research of PIs working on stem cell, genetic, and viral therapy development in the Wisconsin National Primate Center and the Small Animal Imaging and Radiotherapy Facility; and the United States Department of Energy Isotope Production Network. The facility will contribute to meeting projected growth associated with FDA approvals of novel diagnostic and therapeutic radiopharmaceuticals. The proposed facility will more than quadruple existing capacity and add capability to make several new isotopes that are in demand for cutting edge medical diagnostic and therapeutic procedures and research. These capabilities will support the efforts of the UW SMPH and UW Health to help patients with Alzheimer’s and Parkinson’s disease, cancer, chronic pain, and other conditions.

项目摘要/摘要 威斯康星大学 - 麦迪逊分校（UW）的回旋组小组生产医疗和 使用16 MEV通用电气PETTRACE CYCLOTRON的基本科学研究。目前的这项工作 支持UW首席调查员（PIS）领导的2.37亿美元的资助研究，另外9500万美元的LED项目 由全国分布式用户群，估计每年近100万美元的临床服务收入，其自己 联邦内部投资组合每年约120万美元。利益相关者的广泛基础包括 PIS在12个UW部门和超过3个临床研究。核医学最近的增长 回旋器产生的放射线的应用是戏剧性的，需求超过了生产能力 在2022年多次，努力努力对城市大学的临床和基础研究的优先次序 需要。创建独立的UW生产能力，以越来越有前途的单光子发射能力 计算机断层扫描（SPECT）和热放射线，该建议将建立一个新的回旋设施 房屋与现有医学和公共卫生学院（SMPH）相邻的商业30 MEV回旋子 威斯康星州医学研究机构（WIMR）的生物医学研究设施。这台机器会添加 每个必要区域的容量：标准和放射线pet radiouclides，heranotictic beta和螺旋器 - 发射器，以及面向申请的研究。新机器还将增强 现有的Pettrace Cyclotron的功效，将每台机器的努力集中在其优势上，简单地将 支持新生的西澳大学治疗和粒子疗法研究所； Waisman Center和Alzheimer的 疾病研究中心的神经退行性成像试验组合； PIS的临床前研究 威斯康星州灵长类动物中心的干细胞，遗传和病毒疗法发展 动物成像和放射治疗设施；和美国能源同位素生产部 网络。该设施将有助于满足与FDA新颖批准相关的预计增长 诊断和治疗性放射性药物。拟议的设施将不仅仅是四倍的现有 能力并增加能力，以制造几种需要尖端医学诊断的新同位素 以及治疗程序和研究。这些功能将支持UW SMPH和UW的努力 健康以帮助患有阿尔茨海默氏症和帕金森氏病，癌症，慢性疼痛和其他疾病的患者。